Brucellosis Vaccines Market  By Type (RBS1, S19, B19) , By Vaccine (DNA Vaccine, Subunit Vaccine, Vector Vaccine, Recombinant Vaccine) By Animal Type (Cattle, Sheep, Goat) By End User (Veterinary Hospitals and Clinics, Animal Care Centers, Other) : Global

Brucellosis Vaccines Market  By Type (RBS1, S19, B19) , By Vaccine (DNA Vaccine, Subunit Vaccine, Vector Vaccine, Recombinant Vaccine) By Animal Type (Cattle, Sheep, Goat) By End User (Veterinary Hospitals and Clinics, Animal Care Centers, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033

The brucellosis vaccines market was valued at $0.2 billion in 2023, and is projected to reach $0.4 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.
Brucellosis vaccine is a critical tool used in the prevention and control of brucellosis, a zoonotic bacterial infection caused by Brucella species. This disease affects various livestock, including cattle, sheep, and goats, leading to reproductive failures such as abortions, reduced fertility, and significant economic losses in the agricultural sector. In humans, brucellosis can cause a range of symptoms, from mild flu-like illness to severe, chronic conditions. Vaccination of livestock is a cornerstone in reducing the transmission of Brucella from animals to humans, thus playing a vital role in public health and food safety.
The growth of the global brucellosis vaccines market is driven by rise in incidence of brucellosis in livestock, particularly in regions with significant agricultural activity, and increase in awareness among farmers and livestock owners about the importance of vaccination in preventing brucellosis. According to a study published by the National Institutes of Health—one of the world's foremost medical research centers—brucellosis is one the most common zoonotic diseases affecting 500,000 cases annually. As the global demand for meat and dairy products grows, there is a corresponding increase in the need to protect livestock from diseases like brucellosis, further driving the brucellosis vaccine market. Moreover, with brucellosis being a zoonotic disease that can be transmitted to humans, there is an increasing focus on controlling the disease in animals to protect human health, which, in turn, fosters the demand for vaccines. Furthermore, increase in trend of regional and national vaccination campaigns, particularly in countries where brucellosis is a significant public health issue, is notably contributing toward the market growth. In addition, emphasis on the One Health concept, which focuses on the interconnectedness of human, animal, and environmental health, is influencing the brucellosis vaccination market. This holistic approach is leading to integrated efforts to control brucellosis in both animals and humans, particularly in regions where the disease is endemic. However, high cost associated with development of new and effective brucellosis vaccines is hampering the growth of the global market. In addition, the emergence of vaccine-resistant strains of Brucella due to genetic variability has reduced the effectiveness of existing vaccines, which significantly restrained the market growth. On the contrary, advancements in vaccine technology, such as the development of more effective and safer vaccines, are contributing to market growth by improving the efficacy of disease control measures. Moreover, advances in biotechnology are driving innovations in vaccine production, including the use of recombinant DNA technology and other molecular techniques. These innovations are enhancing the efficacy and safety of brucellosis vaccines, making them more accessible and scalable.
The global brucellosis vaccines industry is segmented into type, vaccine, animal type, end user, and region. By type, the market is divided into RBS1, S19, and B19. As per vaccine, it is segregated into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By animal type, it is fragmented into cattle, sheep, and goat. Depending on end user, it is fragmented into veterinary hospitals & clinics, animal care centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the RBS1 segment dominated the market share in 2023.
As per vaccine, the DNA vaccine segment was the major shareholder in the market in 2023.
On the basis of animal type, cattle emerged as the leading segment in 2023.
Depending on end user, the veterinary hospitals & clinics segment garnered the largest share in 2023.
Region wise, North America held the dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global brucellosis vaccines market include Ceva Poultry, Colorado Serum Company, Creative Biolabs, CZ Vaccines, Fivet Animal Health, Hester Biosciences Limited, Indian Immunologicals Ltd, Jordan Bio-industries Center, Laboratories Tornel, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Key Market Segments

By Type

RBS1
S19
B19

By Vaccine

DNA Vaccine
Subunit Vaccine
Vector Vaccine
Recombinant Vaccine

By Animal Type

Cattle
Sheep
Goat

By End User

Veterinary Hospitals and Clinics
Animal Care Centers
Other

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Ceva Poultry
Colorado Serum Company
Creative Biolabs
CZ Vaccines
Fivet Animal Health
Hester Biosciences Limited
Indian Immunologicals Ltd
Jordan Bio-industries Center
Laboratories Tornel
Merck & Co., Inc.